See more : Grupo Elektra, S.A.B. de C.V. (ELEKTRA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of JW Pharmaceutical Corporation (001060.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of JW Pharmaceutical Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aion Therapeutic Inc. (AION.CN) Income Statement Analysis – Financial Results
- Ishizuka Glass Co., Ltd. (5204.T) Income Statement Analysis – Financial Results
- Indus Finance Limited (INDUSFINL.BO) Income Statement Analysis – Financial Results
- I-Minerals Inc. (IMAHF) Income Statement Analysis – Financial Results
- Core Scientific, Inc. (CORZW) Income Statement Analysis – Financial Results
JW Pharmaceutical Corporation (001060.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jw-pharma.co.kr
About JW Pharmaceutical Corporation
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 748.53B | 684.35B | 606.58B | 547.34B | 511.34B | 537.18B | 502.92B | 467.47B | 434.35B | 412.79B | 394.18B | 397.08B | 431.01B | 443.28B | 455.15B | 437.65B | 385.01B |
| Cost of Revenue | 412.85B | 396.40B | 372.21B | 369.81B | 350.22B | 340.14B | 314.29B | 294.12B | 273.73B | 261.52B | 249.70B | 268.11B | 283.01B | 281.78B | 269.09B | 246.93B | 202.05B |
| Gross Profit | 335.67B | 287.95B | 234.38B | 177.53B | 161.12B | 197.04B | 188.63B | 173.34B | 160.62B | 151.27B | 144.48B | 128.98B | 147.99B | 161.49B | 186.05B | 190.71B | 182.96B |
| Gross Profit Ratio | 44.84% | 42.08% | 38.64% | 32.43% | 31.51% | 36.68% | 37.51% | 37.08% | 36.98% | 36.65% | 36.65% | 32.48% | 34.34% | 36.43% | 40.88% | 43.58% | 47.52% |
| Research & Development | 33.67B | 33.74B | 19.88B | 22.94B | 25.22B | 21.27B | 21.98B | 18.00B | 16.48B | 17.48B | 13.46B | 12.36B | 12.01B | 5.83B | 6.05B | 5.72B | 5.92B |
| General & Administrative | 116.77B | 91.22B | 86.21B | 65.84B | 41.93B | 64.72B | 60.28B | 59.67B | 54.02B | 52.31B | 47.91B | 33.09B | 32.74B | 28.96B | 26.48B | 25.80B | 23.75B |
| Selling & Marketing | 35.86B | 35.52B | 29.12B | 26.68B | 39.78B | 26.83B | 24.79B | 23.85B | 21.08B | 19.65B | 18.28B | 20.62B | 23.82B | 26.51B | 44.41B | 49.95B | 44.65B |
| SG&A | 152.64B | 126.74B | 115.34B | 92.52B | 81.71B | 91.55B | 85.07B | 83.51B | 75.10B | 71.96B | 66.20B | 53.71B | 56.56B | 55.47B | 70.89B | 75.75B | 68.39B |
| Other Expenses | 48.93B | 64.70B | 67.95B | 63.39B | 73.20B | 881.20M | 1.95B | -1.56B | 523.11M | -49.86M | 1.33B | 333.47M | 73.20M | -8.42B | -9.67B | -9.56B | -10.07B |
| Operating Expenses | 235.24B | 225.18B | 203.18B | 178.85B | 180.13B | 175.46B | 166.91B | 148.81B | 139.10B | 133.16B | 118.58B | 119.49B | 131.51B | 132.33B | 148.87B | 154.04B | 141.70B |
| Cost & Expenses | 648.22B | 621.57B | 575.39B | 548.66B | 530.35B | 515.60B | 481.20B | 442.93B | 412.83B | 394.68B | 368.28B | 387.60B | 414.52B | 414.11B | 417.97B | 400.98B | 343.75B |
| Interest Income | 5.89B | 5.32B | 1.65B | 628.74M | 128.05M | 9.20M | 114.73M | 560.57M | 1.05B | 571.31M | 1.58B | 167.10M | 170.40M | 1.18B | 1.29B | 1.91B | 1.32B |
| Interest Expense | 12.56B | 9.39B | 7.34B | 7.59B | 11.28B | 8.69B | 8.88B | 12.11B | 14.28B | 17.28B | 20.65B | 24.39B | 24.84B | 17.25B | 13.09B | 9.02B | 6.97B |
| Depreciation & Amortization | 22.44B | 17.19B | 16.11B | 20.69B | 19.56B | 16.95B | 17.90B | 17.76B | 17.86B | 16.62B | 16.15B | 14.36B | 12.84B | 9.04B | 10.43B | 12.45B | 12.65B |
| EBITDA | 89.22B | 73.45B | 45.13B | 15.07B | -2.87B | 39.34B | 27.28B | 38.91B | 36.78B | 34.69B | 39.65B | 23.06B | 26.07B | 35.22B | 39.84B | 40.79B | 41.06B |
| EBITDA Ratio | 11.92% | 12.06% | 7.81% | 2.78% | -0.49% | 7.23% | 5.32% | 7.35% | 7.38% | 8.32% | 10.37% | 6.25% | 6.48% | 7.04% | 9.41% | 8.42% | 10.68% |
| Operating Income | 100.30B | 62.96B | 31.20B | -5.48B | -19.01B | 21.58B | 21.72B | 24.54B | 21.52B | 18.11B | 25.90B | 9.49B | 16.62B | 29.16B | 37.18B | 36.67B | 41.26B |
| Operating Income Ratio | 13.40% | 9.20% | 5.14% | -1.00% | -3.72% | 4.02% | 4.32% | 5.25% | 4.96% | 4.39% | 6.57% | 2.39% | 3.86% | 6.58% | 8.17% | 8.38% | 10.72% |
| Total Other Income/Expenses | -46.09B | -17.60B | -10.67B | -11.88B | -15.32B | -11.35B | -23.07B | -17.46B | -19.47B | -17.32B | -22.49B | -24.64B | -28.11B | -20.24B | -20.86B | -17.35B | -19.81B |
| Income Before Tax | 54.22B | 45.36B | 20.53B | -13.21B | -34.34B | 10.23B | -1.35B | 7.08B | 2.06B | 1.86B | 3.41B | -15.15B | -11.48B | 8.93B | 16.32B | 19.32B | 21.45B |
| Income Before Tax Ratio | 7.24% | 6.63% | 3.38% | -2.41% | -6.71% | 1.91% | -0.27% | 1.51% | 0.47% | 0.45% | 0.86% | -3.82% | -2.66% | 2.01% | 3.59% | 4.41% | 5.57% |
| Income Tax Expense | 16.41B | 15.51B | 21.97B | 2.07B | -9.06B | 2.18B | -605.56M | 18.01B | 95.21M | 414.04M | 1.13B | 5.24B | -1.68B | 3.33B | 5.40B | 12.88B | 12.69B |
| Net Income | 37.01B | 31.89B | -1.44B | -15.28B | -25.28B | 8.06B | -742.47M | -10.93B | 1.96B | 1.45B | 2.27B | -20.39B | -9.80B | 5.60B | 10.92B | 6.43B | 8.76B |
| Net Income Ratio | 4.94% | 4.66% | -0.24% | -2.79% | -4.94% | 1.50% | -0.15% | -2.34% | 0.45% | 0.35% | 0.58% | -5.14% | -2.27% | 1.26% | 2.40% | 1.47% | 2.28% |
| EPS | 1.43K | 1.27K | -62.11 | -657.85 | -1.09K | 298.53 | -65.33 | -515.81 | 57.77 | -164.26 | 131.38 | -1.36K | -679.72 | 377.20 | 732.43 | 427.89 | 505.18 |
| EPS Diluted | 1.43K | 1.27K | -62.11 | -657.85 | -1.09K | 298.53 | -65.33 | -515.81 | 57.77 | -164.26 | 131.38 | -1.36K | -679.72 | 377.20 | 732.43 | 427.89 | 505.18 |
| Weighted Avg Shares Out | 24.61M | 23.92M | 23.21M | 23.22M | 23.21M | 26.99M | 11.36M | 21.20M | 20.70M | 14.35M | 17.32M | 14.99M | 14.42M | 14.85M | 14.91M | 15.03M | 17.34M |
| Weighted Avg Shares Out (Dil) | 24.61M | 23.92M | 23.21M | 23.22M | 23.21M | 26.99M | 11.36M | 21.20M | 20.70M | 14.35M | 17.32M | 14.99M | 14.42M | 14.85M | 14.91M | 15.03M | 17.34M |
Source: https://incomestatements.info
Category: Stock Reports